Novo Nordisk said it plans to invest $2.3 billion to expand a pharmaceutical ingredient production facility in Denmark for its future portfolio within serious chronic diseases.
Novo Nordisk said it plans to invest $2.3 billion to expand a pharmaceutical ingredient production facility in Denmark for its future portfolio within serious chronic diseases.